Sabine Schmid
Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction.
Ul Haq S, Schmid S, Aparnathi M, Hueniken K, Zhan L, Sacdalan D, Li J, Meti N, Patel D, Cheng D, Philip V, Tsao M, Cabanero M, de Carvalho D, Liu G, Bratman S, Lok B. Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction. iScience 2022; 25:105487.
Nov 4, 2022Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction.
Nov 4, 2022iScience 2022; 25:105487
Ul Haq Sami, Schmid Sabine, Aparnathi Mansi K, Hueniken Katrina, Zhan Luna Jia, Sacdalan Danielle, Li Janice J N, Meti Nicholas, Patel Devalben, Cheng Dangxiao, Philip Vivek, Tsao Ming S, Cabanero Michael, de Carvalho Daniel, Liu Geoffrey, Bratman Scott V, Lok Benjamin H
Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
Koster K, Appenzeller C, Lauber A, Früh M, Schmid S. Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Case Rep Oncol 2022; 15:720-725.
Aug 26, 2022Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
Aug 26, 2022Case Rep Oncol 2022; 15:720-725
Koster Kira-Lee, Appenzeller Christina, Lauber Arno, Früh Martin, Schmid Sabine
iRECIST and atypical patterns of response to immuno-oncology drugs.
Ramon-Patino J, Schmid S, Lau S, Seymour L, Gaudreau P, Li J, Bradbury P, Calvo E. iRECIST and atypical patterns of response to immuno-oncology drugs. J Immunother Cancer 2022; 10
Jun 1, 2022iRECIST and atypical patterns of response to immuno-oncology drugs.
Jun 1, 2022J Immunother Cancer 2022; 10
Ramon-Patino Jorge Luis, Schmid Sabine, Lau Sally, Seymour Lesley, Gaudreau Pierre-Olivier, Li Janice Juan Ning, Bradbury Penelope Ann, Calvo Emiliano
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind F, Ellinger J, Brossart P, Diem S, Schmid S, Jörger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J Immunother Cancer 2022; 10
Mar 1, 2022C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Mar 1, 2022J Immunother Cancer 2022; 10
Klümper Niklas, Saal Jonas, Berner Fiamma, Lichtensteiger Christa, Wyss Nina, Heine Annkristin, Bauernfeind Franz Georg, Ellinger Jörg, Brossart Peter, Diem Stefan, Schmid Sabine, Jörger Markus, Frueh Martin, Ritter Manuel, Hölzel Michael, Flatz Lukas, Bald Tobias
Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.
Schmid S, Jiang M, Brown M, Fares A, Garcia M, Soriano J, Dong M, Thomas S, Kohno T, Leal L, Diao N, Xie J, Wang Z, Zaridze D, Holcatova I, Lissowska J, Świątkowska B, Mates D, Savic M, Wenzlaff A, Harris C, Caporaso N, Ma H, Fernandez-Tardon G, Barnett M, Goodman G, Davies M, Pérez-Ríos M, Taylor F, Duell E, Schoettker B, Brenner H, Andrew A, Cox A, Ruano-Ravina A, Field J, Marchand L, Wang Y, Chen C, Tardon A, Shete S, Schabath M, Shen H, Landi M, Ryan B, Schwartz A, Qi L, Sakoda L, Brennan P, Yang P, Zhang J, Christiani D, Reis R, Shiraishi K, Hung R, Xu W, Liu G. Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. Cancer Epidemiol Biomarkers Prev 2022; 31:679-687.
Mar 1, 2022Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.
Mar 1, 2022Cancer Epidemiol Biomarkers Prev 2022; 31:679-687
Schmid Sabine, Jiang Mei, Brown M Catherine, Fares Aline, Garcia Miguel, Soriano Joelle, Dong Mei, Thomas Sera, Kohno Takashi, Leal Leticia Ferro, Diao Nancy, Xie Juntao, Wang Zhichao, Zaridze David, Holcatova Ivana, Lissowska Jolanta, Świątkowska Beata, Mates Dana, Savic Milan, Wenzlaff Angela S, Harris Curtis C, Caporaso Neil, Ma Hongxia, Fernandez-Tardon Guillermo, Barnett Matthew J, Goodman Gary, Davies Michael P A, Pérez-Ríos Mónica, Taylor Fiona, Duell Eric J, Schoettker Ben, Brenner Hermann, Andrew Angeline, Cox Angela, Ruano-Ravina Alberto, Field John K, Marchand Loic Le, Wang Yingbo, Chen Chu, Tardon Adonina, Shete Sanjay, Schabath Matthew B, Shen Hongbing, Landi Maria Teresa, Ryan Brid M, Schwartz Ann G, Qi Lihong, Sakoda Lori C, Brennan Paul, Yang Ping, Zhang Jie, Christiani David C, Reis Rui Manuel, Shiraishi Kouya, Hung Rayjean J, Xu Wei, Liu Geoffrey
Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre.
Schmid S, Zhan L, Dietrich K, Khan K, Chowdhury M, Hermann M, Patel D, Zaeimi F, Leighl N, Sacher A, Feld R, Shepherd F, Donahoe L, de Perrot M, Cho B, Liu G, Bradbury P. Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. Clin Lung Cancer 2021; 23:e43-e53.
Aug 10, 2021Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre.
Aug 10, 2021Clin Lung Cancer 2021; 23:e43-e53
Schmid Sabine, Zhan Luna Jia, Dietrich Kristen, Khan Khaleeq, Chowdhury Maisha, Hermann Michael, Patel Devalben, Zaeimi Fatemeh, Leighl Natasha B, Sacher Adrian, Feld Ronald, Shepherd Frances A, Donahoe Laura, de Perrot Marc, Cho Byoung Chun John, Liu Geoffrey, Bradbury Penelope A
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer 2021; 156:91-99.
Apr 25, 2021Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Apr 25, 2021Lung Cancer 2021; 156:91-99
Froesch Patrizia, Früh Martin, Gautschi Oliver, Sessa Cristiana, König David, Metaxas Yannis, Colombo Ilaria, Schmid Sabine, Oppliger Leibundgut Elisabeth, Rusterholz Corinne, Godar Gilles, Li Qiyu, Rothschild Sacha I, Mark Michael, Swiss Group for Clinical Cancer Research (SAKK)
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Schmid S, De Giorgi U, Hansen A, Beer T, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Bianchini D, Chi K, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen M, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open 2020; 3:e2021692.
Oct 1, 2020Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Oct 1, 2020JAMA Netw Open 2020; 3:e2021692
Schmid Sabine, De Giorgi Ugo, Hansen Aaron R, Beer Tomasz M, Lavaud Pernelle, Morales-Barrera Rafael, Tucci Marcello, Castro Elena, Karalis Kostas, Bergman Andries M, Le Mo Linh, Zürrer-Härdi Ursina, Pezaro Carmel, Suzuki Hiroyoshi, Zivi Andrea, Klingbiel Dirk, Schär Sämi, Bianchini Diletta, Chi Kim N, Omlin Aurelius, Higano Celestia, Sweeney Christopher, Martinez Chanza Nieves, Mehra Niven, Kuppen Malou C P, Beltran Himisha, Conteduca Vincenza, Vargas Pivato de Almeida Daniel, Cotait Maluf Fernando, Oh William K, Tsao Che-Kai, Sartor Oliver, Ledet Elisa, Di Lorenzo Giuseppe, Yip Steven M, Gillessen Silke
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Schmid S, Jochum W, Addeo A, Demmer I, Schär S, Janthur W, Wannesson L, König D, Britschgi C, Frösch P, Bouchaab H, Rothschild S, Blum V, Friedlaender A, Mauti L, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. Cancer Immunol Immunother 2020; 69:1605-1613.
Apr 19, 2020Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Apr 19, 2020Cancer Immunol Immunother 2020; 69:1605-1613
Schmid Sabine, Jochum Wolfram, Addeo Alfredo, Demmer Izadora, Schär Sämi, Janthur Wolf-Dieter, Wannesson Luciano, König David, Britschgi Christian, Frösch Patrizia, Bouchaab Hasna, Rothschild Sacha I, Blum Veronika, Friedlaender Alex, Mauti Laetitia A, Früh Martin
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Schmid S, Früh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?. Lancet Oncol 2020; 21:320-322.
Feb 3, 2020Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Feb 3, 2020Lancet Oncol 2020; 21:320-322
Schmid Sabine, Früh Martin, Peters Solange
Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland
Schmid S, Suipyte J, Herrmann C, Mousavi M, Hitz F, Früh M. Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. Eur J Cancer Care (Engl) 2020; 29:e13206.
Jan 21, 2020Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland
Jan 21, 2020Eur J Cancer Care (Engl) 2020; 29:e13206
Schmid Sabine, Suipyte Jorune, Herrmann Christian, Mousavi Mohsen, Hitz Felicitas, Früh Martin
Progress in therapy across the spectrum of advanced prostate cancer
Schmid S, Omlin A. Progress in therapy across the spectrum of advanced prostate cancer. Nat Rev Urol 2019
Dec 16, 2019Progress in therapy across the spectrum of advanced prostate cancer
Dec 16, 2019Nat Rev Urol 2019
Schmid Sabine, Omlin Aurelius
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC cancer 2019; 19:902.
Sep 10, 2019Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sep 10, 2019BMC cancer 2019; 19:902
Schmid Sabine, Zaman Khalil, Weder Patrik, von Moos Roger, Thürlimann Beat, Rochlitz Christoph, Pestalozzi Bernhard, Pagani Olivia, Oehlschlegel Christian, Nolè Franco, Munzone Elisabetta, Mamot Christoph, Goldhirsch Aron, Aebi Stefan, Klingbiel Dirk, Ruhstaller Thomas
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. Eur Urol Oncol 2019
Jul 12, 2019Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Jul 12, 2019Eur Urol Oncol 2019
Rescigno Pasquale, Romero-Laorden Nuria, Castro Elena, Saez Maria I, Mehra Niven, Smeenk Stella, Sideris Spyridon, Gil Thyerry, Banks Patricia, Sandhu Shaneen K, Sternberg Cora N, De Giorgi Ugo, Olmos David, Morley Courtney, Pezaro Carmel J, Dolling David, Conteduca Vincenza, Rediti Mattia, Bianchini Diletta, Lolli Cristian, Ong Michael, Li Haoran, Omlin Aurelius, Schmid Sabine, Caffo Orazio, Zivi Andrea, de Bono Johann S
Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model
Betschart P, Schmid H, Klingbiel D, Engeler D, Gillessen Sommer S, Schwab C, Abt D, Rothermundt C, Schmid S, Babst C, Omlin A. Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. Oncol Res Treat 2019; 42:366-374.
Jun 6, 2019Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model
Jun 6, 2019Oncol Res Treat 2019; 42:366-374
Betschart Patrick, Schmid Hans-Peter, Klingbiel Dirk, Engeler Daniel, Gillessen Sommer Silke, Schwab Christoph, Abt Dominik, Rothermundt Christian, Schmid Sabine, Babst Christa, Omlin Aurelius
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort
Schmid S, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. Lung Cancer 2019
Mar 5, 2019Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort
Mar 5, 2019Lung Cancer 2019
Schmid Sabine, Aeppli Stefanie, Früh Martin
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019; 130:149-155.
Feb 19, 2019Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Feb 19, 2019Lung Cancer 2019; 130:149-155
Schmid Sabine, Jochum Wolfram, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli Stefanie, Klingbiel D, Früh Martin
Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys
Mousavi S, Schmid S, Cerny T, Früh M. Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys. Swiss Med Wkly 2018; 148:w14708.
Dec 30, 2018Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys
Dec 30, 2018Swiss Med Wkly 2018; 148:w14708
Mousavi Seyed Mohsen, Schmid Sabine, Cerny Thomas, Früh Martin
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
Nov 8, 2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Nov 8, 2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018
Aug 31, 2018Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Aug 31, 2018Cancer Immunol Immunother 2018
Schmid Sabine, Jochum Wolfram, Klingbiel Dirk, Desbiolles Lotus, Leschka Sebastian, Flatz Lukas, Krapf Mirjam, Li Qiyu, Diem Stefan, Früh Martin